Synapse - Min Yuen Teo

Results (106)

Clinical outcomes, genomic heterogeneity, and therapeutic considerations across histologic subtypes of urothelial carcinoma

Journal Article

Chu, C. E.; Chen, Z.; Whiting, K.; Ostrovnaya, I.; Lenis, A. T.; Clinton, T. N.; Rammal, R.; Ozcan, G. G.; Akbulut, D.; Basar, M.; more...
European Urology (2025)

Fulltext@MSK | Save

Real-world clinical outcomes of sacituzumab govitecan after prior exposure to enfortumab vedotin in patients with metastatic urothelial carcinoma

Journal Article

Sternschuss, M.; Toumbacaris, N.; Das, J. P.; Powles, T.; Kotecha, R. R.; Laccetti, A. L.; Xiao, H.; Feld, E.; McHugh, D. J.; Keegan, N. M.; more...
ESMO Open (2025)

Fulltext@MSK | Save

Characterizing the immune effects of enfortumab vedotin (EV) on peripheral blood mononuclear cells (PBMCs) in metastatic urothelial cancer patients (mUC)

Meeting Abstract

Gupta, A.; Sevilla, C.; Pihlstrom, N. L.; Liang, S.; Regazzi, A. M.; McCoy, A. S.; Maher, C. A.; Wong, P.; Ahmed, F.; Funt, S. A.; more...
Journal of Clinical Oncology (2025)

Fulltext@MSK | Save

Updated long-term follow-up from a phase II clinical trial of gemcitabine and cisplatin as neoadjuvant chemotherapy for patients with high-grade upper tract urothelial carcinoma

Meeting Abstract

Jayalath, V.; Teo, M. Y.; Assel, M.; Rodriguez, D.; Meyerson, A.; Bochner, B. H.; Dalbagni, G.; Donat, S. M.; Herr, H. W.; Cha, E. K.; more...
Journal of Clinical Oncology (2025)

Fulltext@MSK | Save

Adjuvant pembrolizumab versus observation in muscle-invasive urothelial carcinoma

Journal Article

Apolo, A. B.; Ballman, K. V.; Sonpavde, G.; Berg, S.; Kim, W. Y.; Parikh, R.; Teo, M. Y.; Sweis, R. F.; Geynisman, D. M.; Grivas, P.; more...
New England Journal of Medicine (2025)

Fulltext@MSK | Save

Clinical outcomes of patients with metastatic urothelial carcinoma (mUC) discontinuing enfortumab vedotin (EV) monotherapy (mono) without disease progression

Meeting Abstract

Sternschuss, M.; Whiting, K.; Teo, M. Y.; Bajorin, D.; Kotecha, R.; Laccetti, A. L.; Xiao, H.; Feld, E.; McHugh, D. J.; Keegan, N.; more...
Annals of Oncology (2024)

Fulltext@MSK | Save

Alliance A031501: AMBASSADOR study of adjuvant pembrolizumab (Pembro) in muscle-invasive urothelial carcinoma (MIUC) vs observation (Obs): Extended follow-up disease-free survival (DFS) results and metastatic (met) disease recurrence distribution

Meeting Abstract

Apolo, A. B.; Ballman, K.; Sonpavde, G. P.; Berg, S.; Kim, W.; Parikh, R.; Teo, M. Y.; Sweis, R. F.; Geynisman, D.; Grivas, P.; more...
Annals of Oncology (2024)

Fulltext@MSK | Save

AMBASSADOR Alliance A031501: Phase III randomized adjuvant study of pembrolizumab in muscle-invasive and locally advanced urothelial carcinoma (MIUC) vs observation

Meeting Abstract

Apolo, A. B.; Ballman, K. V.; Sonpavde, G. P.; Berg, S. A.; Kim, W. Y.; Parikh, R. A.; Teo, M. Y.; Sweis, R. F.; Geynisman, D. M.; Grivas, P.; more...
Journal of Clinical Oncology (2024)

Fulltext@MSK | Save

HER2 and PD-L1 immunohistochemistry (IHC) expression, and HER2 genomic alterations: Associations and clinical outcomes for advanced bladder cancer

Meeting Abstract

Aggen, D. H.; Shah, N. J.; Zheng, J.; Alam, S. M.; Balar, O.; Niederhausern, A.; Regazzi, A. M.; Ratna, N.; Funt, S. A.; Teo, M. Y.; more...
Journal of Clinical Oncology (2024)

Fulltext@MSK | Save

HER2 mutation and bladder cancer (BC): Prevalence and clinical outcomes

Meeting Abstract

Shah, N. J.; Aggen, D. H.; Zheng, J.; Niederhausern, A.; Alam, S. M.; Balar, O.; Bahadur, N.; Watson, A.; Regazzi, A. M.; Ratna, N.; more...
Journal of Clinical Oncology (2024)

Fulltext@MSK | Save